SecBot SecBot
8-K ·Filed May 14, 2026

ELUT

ELUTIA INC.
NEUTRAL
Impact 5/10
Horizonmonths Processed6mo ago SEC0001104659-26-061150
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The stock trades on NXT-41x pipeline milestones, not current financials. Watch for FDA clearance of NXT-41 in Q4 2026 and any SimpliDerm/Cardiovascular divestiture announcements that could extend cash runway. The $8.0M escrow release in Q4 2026 is a near-term liquidity catalyst.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.03
T+0 close · May 14, 2026 · via day close
Latest settled
−22.18%
T+60 · $0.8015
Vs SPY
−26.70%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 15 $1.03entry
  2. T+1 · 6mo ago +6.80%α +6.86% · $1.10
  3. T+5 · 6mo ago +12.62%α +11.66% · $1.16
  4. T+20 · 5mo ago −5.92%α −8.04% · $0.9690
  5. T+60 · 3mo ago −22.18%α −26.70% · $0.8015

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Elutia reported Q1 2026 revenue of $3.1M (+6% YoY) and a GAAP net loss of $7.5M, widening from a $3.9M loss in Q1 2025, driven by a $6.7M non-cash swing in warrant liability revaluation. The core story remains the NXT-41x pipeline, with FDA clearance for NXT-41 on track for Q4 2026 and NXT-41x for 1H27, supported by a new automated manufacturing process targeting >80% gross margins at scale. The balance sheet is stable with $36.5M in cash and escrow, but the company is pre-revenue on its key catalyst and burning ~$4.4M in adjusted EBITDA per quarter.

Key Financial Metrics

EPS
−$0.17
Revenue
$3.1M
+5.5% YoY
Rating
in line
Gross Margin
57.9%

Key Facts

  • Q1 2026 net sales $3.1M, up 6% from $3.0M in Q1 2025
  • GAAP net loss $7.5M vs $3.9M loss in Q1 2025, driven by non-cash warrant revaluation swing
  • Adjusted EBITDA loss widened to $4.4M from $2.8M in Q1 2025
  • Cash and escrow $36.5M ($28.5M cash + $8.0M escrow), expected to fund operations into 2027
  • NXT-41 510(k) clearance on track for Q4 2026; NXT-41x clearance anticipated 1H27
  • New automated manufacturing process installed, targeting >80% gross margins at scale
  • Strategic processes for SimpliDerm and Cardiovascular product lines advancing
  • 44.2M Class A shares outstanding plus 3.2M pre-funded warrants as of March 31, 2026

Financial Impact

Quarterly revenue $3.1M, net loss $7.5M, adjusted EBITDA loss $4.4M

revenuenet lossadjusted EBITDAcash burn

Risk Factors

  • FDA clearance delays for NXT-41 or NXT-41x
  • Cash burn of ~$4.4M/quarter adjusted EBITDA could require additional financing before NXT-41x commercialization
  • Dilution risk from 3.2M pre-funded warrants outstanding
  • SimpliDerm and Cardiovascular revenue declining (SimpliDerm -19% YoY) as focus shifts to NXT-41x

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-061150
Document: elut-20260514x8k.htm0001104659-26-061150
Document: 0001104659-26-061150-index-headers.html0001104659-26-061150
Document: 0001104659-26-061150-index.html0001104659-26-061150
Document: 0001104659-26-061150.txt0001104659-26-061150
8-K Data (Synthetic)0001104659-26-061150

Track record

7 reports on ELUT

Performance horizon
Filters
  1. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
  2. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $0.8374 Now $0.8230 −1.72% settles Dec 7
  3. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $0.8615 Now $0.8230 −4.47% settles Nov 20
  4. Jul 31, 202615w ago Press Release Neutral 1/10 Entry $0.8568 to $0.8800 Now $0.8230 −3.94% ▲ +2.71% −0.28% vs SPY
  5. Jun 16, 202621w ago 8-K Neutral 3/10 Entry $0.9914 to $0.9500 Now $0.8230 −16.99% ▼ −4.18% −5.49% vs SPY
  6. May 14, 202626w ago 8-K Neutral 5/10 Viewing Entry $1.03 to $0.9690 Now $0.8230 −20.10% ▼ −5.92% −8.04% vs SPY
  7. Mar 11, 202635w ago 8-K Mixed 7/10 Entry $1.15 to $1.13 Now $0.8230 −28.43% ▼ −1.74% −3.71% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026